On November 9, Eli Lilly and Company received an Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration for the investigational monoclonal antibody treatment bamlanivimab. The EUA allows healthcare providers to administer bamlanivimab to non-hospitalized patients with confirmed COVID-19 who are experiencing mild to moderate symptoms and are at high-risk for severe symptoms and hospitalization. This page describes this antibody treatment and the allocation and distribution process. COVID-19 Clinical Rounds Peer-to-Peer Virtual Communities of Practice are a collaborative effort between ASPR, the National Emerging Special Pathogen Training and Education Center (NETEC), and Project ECHO. These interactive virtual learning sessions aim to create a peer-to-peer learning network where clinicians from the U.S. and abroad who have experience treating patients with COVID-19 share their challenges and successes; a generous amount of time for participant Q & A is also provided. These webinar topics are covered every week: - EMS: Patient Care and Operations (Mondays, 12:00-1:00 PM ET)
- Critical Care: Lifesaving Treatment and Clinical Operations (Tuesdays, 12:00-1:00 PM ET)
- Emergency Department: Patient Care and Clinical Operations (Thursdays, 12:00-1:00 PM ET)
Access previous webinars and sign up today to receive information on upcoming webinars. The Healthcare & Public Health Sector Partnership led by ASPR’s Division of Critical Infrastructure Protection is actively engaged in responding to COVID-19. Register here to receive regular response bulletins. |